Metabolite Signature of Life's Essential 8 and Risk of Coronary Heart Disease among

Low-Income Black and White Americans

Kui Deng[1], Deepak K. Gupta[2], Xiao-Ou Shu[1], Loren Lipworth[1], Wei Zheng[1], Victoria E.

Thomas[2], Hui Cai[1], Qiuyin Cai[1], Thomas J. Wang[3], Danxia Yu[1]

[1] Division of Epidemiology, Department of Medicine, Vanderbilt University Medical Center,

Nashville, TN, USA

[2] Vanderbilt Translational and Clinical Cardiovascular Research Center and Division of

Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center,

Nashville, TN, USA

[3] Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas,

Texas, USA

Correspondence: Danxia Yu, Division of Epidemiology, Vanderbilt University Medical

Center, 2525 West End Avenue, Nashville, TN, USA 37203, Phone: (+1) 615-936-7389, Fax:

(+1) 615-343-5938, Email: danxia.yu@vumc.org

Abstract

Background and Aims: Life's Essential 8 (LE8) is a comprehensive construct of cardiovascular health. Yet, little is known about LE8 score, its metabolic correlates, and their predictive implications among Black Americans and low-income individuals.

Methods: In a nested case-control study of coronary heart disease (CHD) among 598 Black and 596 White low-income Americans, we estimated LE8 score, conducted untargeted plasma metabolites profiling, and used elastic net with leave-one-out cross-validation to identify metabolite signature (MetaSig) of LE8. Associations of LE8 score and MetaSig with incident CHD were examined using conditional logistic regression. Mediation effect of MetaSig on the LE8-CHD association was also examined. The external validity of MetaSig was evaluated in another nested CHD case-control study among 598 Chinese adults.

Results: Higher LE8 score was associated with lower CHD risk [standardized OR (95% CI)=0.61 (0.53-0.69)]. The identified MetaSig, consisting of 133 metabolites, showed strong correlation with LE8 score (r=0.61) and inverse association with CHD risk [OR (95% CI)=0.57 (0.49-0.65)], robust to adjustment for LE8 score and across participants with different sociodemographic and health status (ORs: 0.42-0.69; all $P<0.05$). MetaSig mediated a large portion of the LE8-CHD association: 53% (32%-80%) ($P<0.001$). Significant associations of MetaSig with LE8 score and CHD risk were found in validation cohort [r=0.49; OR (95% CI)=0.57 (0.46-0.69)].

Conclusions: Higher LE8 score and its MetaSig were associated with lower CHD risk among low-income Black and White Americans. Metabolomics may offer an objective and comprehensive measure of LE8 score and its metabolic phenotype relevant to CHD

40   prevention among diverse populations.

42   **Keywords:** Life's Essential 8; Cardiovascular Health; Coronary Heart Disease; Multi-racial

43   Population; Metabolomics

Introduction

Coronary heart disease (CHD) is a leading cause of morbidity and mortality in the United States (US) and worldwide, with significant and persistent sociodemographic disparities[1,2]. To reduce the burden and life lost due to CHD and other cardiovascular disease (CVD), the American Heart Association (AHA) has recently proposed Life's Essential 8 (LE8) to assess and promote cardiovascular health (CVH) in individuals and populations[3]. LE8 includes 4 health behaviors (healthy diet, participation in physical activity, avoidance of nicotine, and healthy sleep [a new component of LE8]) and 4 health factors (weight, blood lipids, glucose, and blood pressure), and has a new scoring system with continuous scale to better reflect inter-individual differences. While a higher LE8 score has been recently associated with lower CVD incidence and mortality[4-7], few studies have evaluated LE8 score and its association with incident CVD among Black and White Americans who have low socioeconomic status (SES) and face disproportionate CVD burdens. In addition, although some potential mechanisms have been identified (e.g., reduced inflammation and atherosclerosis)[8,9], beyond those known CVD risk pathways, mechanisms and inter-individual differences underlying the cardioprotective effects of LE8 and its included health behaviors and health factors are not fully understood.

Metabolite profiling ("metabolomics") comprehensively measures small-molecule metabolites (including substrates, intermediates, and end products) in biological samples and represents a powerful tool for mechanistic investigation, novel biomarker discovery, and precision medicine[10,11]. Metabolite profiling of blood samples may improve assessments of

individuals' alignment with LE8, particularly for behavioral factors that are prone to survey

and recall biases. In addition, circulating metabolites related to LE8 may capture varied

individual metabolic responses to LE8, providing novel mechanistic insights into its

cardioprotective effects and informing precision medicine. While previous studies have

identified metabolites related to the components of LE8, including diet[12-16], physical

activity[17-19], tobacco exposure[20-22], sleep[23-26], and body mass index (BMI)[27,28], to our

knowledge, no study has applied untargeted plasma metabolomics to identify a

comprehensive metabolite signature (MetaSig) for LE8 to enable studies with incident CHD.

Given that those health behaviors and factors often correlate and interact with each other,

investigating whether plasma metabolomics could provide a good objective assessment of

individuals' alignment with and metabolic responses to overall LE8 and uncovering potential

pathways linking LE8 to incident CHD is highly warranted.

Here, leveraging a case-control study of CHD nested within the Southern Community

Cohort Study (SCCS) involving 598 Black Americans and 596 White Americans, we

assessed the LE8 score and its MetaSig and examined their relations to incident CHD. The

results were further replicated in another nested CHD case-control study of racially and

geographically different population: 598 Chinese adults from the Shanghai Women's Health

Study and Shanghai Men's Health Studies (SWMHS). In addition, we identified MetaSigs for

the health behaviors and health factors recommended in the LE8 and evaluated their

associations with incident CHD.

Methods

Study participants

This study was based on a nested case-control study of CHD within the SCCS[29]. Briefly, the SCCS enrolled 84,735 primarily low-income, uninsured/underinsured Black and White Americans aged 40-79 years from 12 southeastern US states between 2002-2009, with >50% having household income less than $15,000/y and ~86% were uninsured or underinsured[29]. Participants were surveyed for a wide range of information at baseline and followed up regularly for morbidity and mortality outcomes. Venous blood samples were collected at baseline, and plasma samples were aliquoted and stored at -80°C for long-term use. A nested case-control study of CHD within SWMHS was used as the validation cohort, which enrolled 74,940 women, aged 40-70 years, and 61,480 men, aged 40-74 years, from Shanghai, China between 1996–2000 and 2002–2006, respectively[30,31]. These cohort studies were approved by the Institutional Review Boards of the Vanderbilt University Medical Center, Meharry Medical College, and/or Shanghai Cancer Institute. Informed consent was obtained from all enrolled participants.

For the nested case-control studies, participant inclusion criteria were 1) no history of CHD, stroke, heart failure, cancer, or end-stage renal disease at baseline; 2) available baseline plasma samples and data on fasting time and in SCCS, time between sample collection and lab processing; 3) no use of antibiotics nor cold/flu in last 7 days before blood collection. In addition, to facilitate CHD case identification and adjudication, in SCCS, participants were eligible for Centers for Medicare & Medicaid Services (CMS) and had ≥2 claims after cohort

enrollment; in SWMHS, participants' medical records were accessible for our study. In

SCCS, nonfatal CHD cases were identified through CMS, including acute myocardial

infarction, coronary revascularization, and other acute CHD, and CHD deaths were identified

through the National Death Index. In SWMHS, CHD cases were first identified by self-

reported diagnoses during follow-up visits and then confirmed by medical records. In each

race (Black, White, or Chinese) and gender (male or female), 150 incident CHD cases were

randomly selected and 1:1 matched with controls who had no CHD, heart failure, stroke, nor

cancer at the time of case diagnosis, by enrollment age (±2 years), fasting time (±2 hours),

and time between sample collection and lab processing (±4 hours, for SCCS samples; all

SWMHS samples were processed within 6 hours after collection). After excluding eight

plasma samples that did not pass the metabolite profiling quality control, a total of 1792

participants, including 597 pairs of CHD cases and controls in SCCS (299 pairs of Black

Americans and 298 pairs of White Americans), and 299 pairs of Chinese adults in SWMHS

were included in the present study (**Fig. 1**).

Life's Essential 8

We constructed each LE8 component metric and total LE8 score (ranging from 0 to 100)

according to AHA guidelines[3,32], with some modifications based on the characteristics of our

data, as shown in **Table S1**. Briefly, dietary quality was assessed by the Dietary Approaches

to Stop Hypertension (DASH) score[33-35]. Physical activity was measured by total minutes of

leisure-time moderate and vigorous physical activity per week, with each minute of vigorous

physical activity counted as 2 minutes toward the total minutes. Nicotine exposure was

assessed by active tobacco smoking and secondhand smoking exposure. Sleep health was

measured by average self-reported sleep hours per day. BMI was calculated as weight

(kg)/height (m)^2. Blood lipids component was assessed by non-HDL cholesterol (mg/dL)

(plasma total cholesterol minus HDL cholesterol). Because concentrations of fasting glucose

and HbA1c were not measured in our study, blood glucose component was scored based on

diabetes diagnosis and medications and relative abundance of plasma glucose measured

simultaneously with other metabolites (see following metabolite profiling methods). Blood

pressure was unavailable in SCCS, thus blood pressure component was scored based on

hypertension status and medications. Total LE8 score was obtained by calculating the

arithmetic mean of individual component scores. We also calculated scores reflecting

alignment with health behaviors and health factors.

Metabolite profiling

Baseline plasma samples of selected CHD case-control pairs were retrieved and placed

adjacently in the same assay batch. Laboratory persons were blinded to the case-control status

of samples. Untargeted metabolite profiling was performed using ultra-high-performance

liquid chromatography (UHPLC) coupled with tandem mass spectrometry (MS) by

Metabolon Inc. (Morrisville, NC, USA) following a standard assay protocol[36]. Briefly,

plasma samples were extracted with methanol and split into four aliquots for analysis by

UHPLC-MS/MS in both positive and negative ion modes using a combination reverse phase

and HILIC chromatography methods. Metabolites were identified by automated comparison

of mass spectra features to a reference library of >4,000 authenticated standard compounds

followed by visual inspection for quality control. Peaks were quantified using area-under-the-

curve. A total of 1502 metabolites were detected in our samples. The majority of metabolites

(>80%) were annotated based on internal standards. Metabolites that were annotated only by

a match to a known MS spectrum or chemical formula were marked by '*' and '**',

respectively. We excluded metabolites detected in <10% of participants, resulting in 1322

metabolites. Metabolites with missing values were imputed by half of the minimal value in

the non-missing samples. The values of all metabolites were log-transformed and

standardized to mean 0 and unit variance.

Statistical analysis

The characteristics of the study participants were presented as mean (standard deviation

[SD]) for continuous variables and frequency (percentage) for categorical variables.

Spearman correlations between LE8 score and individual component scores were assessed.

Elastic net regression was used to identify metabolites associated with LE8[12,14,37], with

hyperparameters determined via a ten-repeated tenfold cross-validation framework, using R

package caret (version: 6.0-88)[38] and glmnet (version: 4.1-3)[37,39]. The MetaSig was calculated

through a leave-one-out cross-validation approach. In addition, we externally validated the

identified signature in SWMHS using weights of the selected metabolites from SCCS. We

calculated *Spearman* correlations between LE8 score and MetaSig among all participants and

by race, sex, age (≥60y/<60y), incident CHD status, diabetes status, hypertension status,

dyslipidemia status, and fasting status.

176   We then examined the associations of LE8 and its MetaSig with risk of CHD using

177 conditional logistic regression, adjusting for age, education, income, alcohol intake, and

178 family history of CHD. We also included LE8 score and MetaSig in the same model to assess

179 their independent associations with CHD and potential mediating effect of MetaSig on LE8-

180 CHD association. The potential multicollinearity was assessed by variance inflation factor

181 (VIF) using R package car (version: 3.1-0) with VIF >10 indicating multicollinearity among

182 variables. The ranges of VIF for LE8 score and its MetaSig were 1.08-1.37, confirming no

183 multicollinearity. The mediation analysis was performed using R package mediation (version:

184 4.5.0)[40]. Subgroup analyses to evaluate the associations of LE8 and MetaSig with incident

185 CHD were performed by race, age group, sex, education, household income, diabetes status,

186 hypertension status, and dyslipidemia status, with P value for interaction obtained from the

187 corresponding interaction term in the model.

189   The same methods were used to identify MetaSigs for health behaviors and health factors

190 included in LE8 and evaluate their associations with incident CHD, potential mediation

191 effects, and their external validity. Mutual adjustments of health behaviors and health factors

192 score were performed in corresponding statistical models. All analyses were performed using

193 R (version 4.1.1). Two-sided $P < 0.05$ was considered statistically significant. An overview of

194 our study design is presented in **Fig. 1**.

Results

Baseline characteristics of study participants

The mean age at baseline (blood collection) was 55 years in our study participants (**Table**

1). The mean (SD) of LE8 score was 48.1 (12.3) in Black women, 50.0 (13.6) in Black men,

48.1 (13.4) in White women, and 48.5 (14.4) in White men. The median follow-up time for

incident CHD cases was 5 (interquartile range: 3-8) years in SCCS. Incident CHD cases had

significantly lower total LE8 score, health behaviors score, and health factors score than

controls (all P <0.05). The characteristics of participants in SWMHS (mean age: 61 years;

mean LE8 score: 57.2 in women and 50.7 in men) are shown in **Table S2**. There were

moderate correlations between total LE8 score and individual component scores (r ranged

from 0.22 with smoking to 0.47 with BMI and blood pressure scores in SCCS; **Fig. S1**).

Metabolite signature of LE8

We identified 133 metabolites related to LE8 (top 30 are shown in **Fig. 2A**; the full list

can be found in **Table S3**). The MetaSig was strongly correlated with LE8 score ($r = 0.61$,

P<0.001; **Fig. 2B**), meanwhile variations in MetaSig were observed among individuals with

the same LE8 score, demonstrating interindividual difference in metabolic phenotype of LE8.

MetaSig was also correlated with LE8 score in SWMHS ($r = 0.49$, P<0.001; **Fig. 2C**).

Stratified analyses showed that correlations between LE8 score and MetaSig were consistent

regardless of age, sex, race, fasting status, diabetes status, hypertension status, dyslipidemia

status, and incident CHD status (r ranged from 0.54 to 0.64; **Table S4**), suggesting the

robustness of our identified LE8 metabolite signature across participants with different

sociodemographic backgrounds and metabolic disease status.

Associations with incident CHD

Higher LE8 score and its MetaSig were significantly associated with lower risk of CHD:

standardized multivariable-adjusted odds ratio (OR) = 0.61 (95% CI: 0.53-0.69) for LE8

score and 0.57 (0.49-0.65) for MetaSig; both $P < 0.001$ (**Table 2**). Sensitivity analysis

showed that the MetaSig-CHD associations did not change after excluding any individual

metabolites from the signature (**Table S5**). After further adjusting for LE8 score, the

MetaSig-CHD association was only slightly attenuated [OR (95% CI) = 0.66 (0.55-0.78);

$P<0.001$; **Table 2**], suggesting circulating metabolites may complement LE8 assessment and

contribute to CHD risk beyond LE8 score. On the other hand, the LE8-CHD association was

moderately attenuated after adjusting for MetaSig [OR (95% CI) = 0.78 (0.66-0.92),

$P=0.003$]. Mediation analysis showed that MetaSig mediated a large portion of the LE8-CHD

association [53% (32%-80%); $P_{mediation}<0.001$; **Fig. 2D**].

Both LE8 and its MetaSig were inversely associated with CHD risk in subpopulations by

race, age group, education, income, diabetes status, hypertension status, and dyslipidemia

status ($P_{interaction}>0.05$; **Fig. 3**), with stronger associations observed in women than in men [for

LE8, OR (95% CI) = 0.53 (0.42-0.66) in women and 0.66 (0.55-0.80) in men, $P_{interaction} =$

0.017; for MetaSig, 0.48 (0.38-0.6) in women and 0.65 (0.54-0.78) in men, $P_{interaction} = 0.016$].

The association of MetaSig with incident CHD was replicated in SWMHS (**Table 2),**

with OR (95% CI) = 0.57 (0.46-0.69) and 0.69 (0.55-0.86) after further adjusting for LE8

score (both $P<0.001$). The MetaSig also mediated a considerable portion of the LE8-CHD

association in SWMHS [27.4% (10%-47%); $P_{mediation}$<0.001; **Fig. 2E**].

Metabolite signatures of health behaviors and health factors and associations with CHD

We further identified MetaSigs for health behaviors (**Fig. S2A**) and health factors in

SCCS (**Fig. S3A**; full lists of metabolites are shown in **Table S3**), which showed strong

correlations with health behaviors score (r = 0.59, P<0.001; **Fig. S2B**) and with health factors

score (r = 0.76, P<0.001; **Fig. S3B**). Significant correlations were also found among

participant subgroups (**Table S4**), suggesting the robustness of identified metabolite

signatures for health behaviors and health factors. In addition, there were significant inverse

associations of health behaviors score, health factors score, and their related signatures with

risk of CHD (all P<0.001; **Table 2**). Specifically, standardized OR (95% CI) was 0.73 (0.63-

0.85) for health behaviors MetaSig and 0.57 (0.49-0.66) for health factors MetaSig. Similarly,

metabolites mediated large portions of the health behaviors-CHD association [43.9% (13.9%-

101%), P=0.004; **Fig. S2D**] and health factors-CHD association [53.2% (24.8%-89%),

$P_{mediation}$<0.001; **Fig. S3D**]. Further, all results on health behaviors MetaSig and health factors

MetaSig were replicated in SWMHS (**Table 2**, **Fig. S2**, and **Fig. S3**).

Discussion

Leveraging untargeted plasma metabolites data in a nested case-control study among

low-income Black and White Americans, we identified a metabolite signature that could

reflect LE8 score and was associated with incident CHD, even after adjusting for LE8 and

among participants with varied sociodemographic and metabolic health status, suggesting

that circulating metabolite profiling may be used to help assess LE8 alignment across diverse

populations and offer additional information on CVH (e.g., inter-individual metabolic

phenotypes related to LE8). We also identified MetaSigs for health behaviors and health

factors and found consistent results showing that circulating metabolites could reflect the

alignment with those recommendations and underlying metabolic phenotypes, which were

further linked to incident CHD across diverse populations. All the results were further

replicated in another nested case-control study of CHD among Chinese adults. Our findings

demonstrate the potential utility of blood metabolomics to improve the assessment of LE8

and its underlying metabolic variations that are linked to incident CHD among

sociodemographically diverse populations, towards advancing precision medicine and

addressing disparities in CVH.

LE8 is the American Heart Association's updated and enhanced guideline to measure and

promote CVH for individuals and populations[3]. The beneficial associations of following the

LE8 with lower risks of CHD, CVD, and related mortality have been demonstrated in recent

studies[4-7]. However, multi-racial/ethnic populations with low SES remain underrepresented in

research studies, even though they have persistently experienced worse CVH and CVD

outcomes, as well as systemic disadvantages to improve CVH, than White and middle-class

Americans[2,41-43]. Leveraging resources from SCCS, a large cohort of predominantly low-

income Black and White Americans (in the present study: ~65% with household income

<$15,000/y and ~95% with household income <$25,000/y), our study assessed CVH based

on LE8 and evaluated the association of LE8 score with incident CHD. We found that higher

LE8 score (per SD increase) was associated with ~40-50% lower risk of CHD among Black

Americans and individuals with low SES. While LE8 provides a comprehensive approach to

quantify CVH, its assessment involves a series of procedures such as questionnaires,

anthropometric and blood pressure measures, and blood draw. Particularly, health behaviors

(diet, physical activity, smoking, and sleep) are usually assessed by questionnaires, which are

time-consuming and prone to measurement errors and low compliance (particularly in the

clinical setting). Also, LE8 score cannot capture varied individual metabolic responses to

lifestyle exposures. Hence, we incorporated untargeted plasma metabolomics data, and for

the first time, identified a robust metabolite signature of LE8 and then examined its

association with incident CHD.

Metabolomics has been demonstrated as a powerful tool for improving exposure

assessment and identifying potential novel biomarkers and mechanistic pathways in

population studies, given its high-throughput characterization of thousands of metabolites in a

small amount of biological samples[44]. Our study provides new evidence that plasma

metabolite profiling may provide objective and comprehensive measures of LE8 and CVH

among racially and geographically diverse populations. The identified metabolite signature

may complement LE8 scores, improve the precision to stratify individuals with different

future CHD risk, and potentially facilitate personalized CHD prevention strategies.

Our identified MetaSig consists of metabolites reflecting participants' alignment with

LE8 health behaviors and metabolic health status, majority of which are lipids and amino

306 acids, and many of them have been linked to diet[12-16], physical activity[17-19], smoking[20-22],

307 sleep[23-26], obesity[27,28,45], or composite lifestyles scores[46-49] in previous studies. For example,

308 (2,4 or 2,5)-dimethylphenol sulfate, tartronate, and ethyl beta-glucopyranoside are derived

309 from plant-based foods; cotinine is the major metabolite of nicotine from tobacco smoking;

310 cholesterol, sphingomyelin, cortisol, and 1-palmitoleoylglycerolare are related to blood

311 lipids; mannose, metformin, and fructosyllysine are related to prevalent diabetes and blood

312 glucose. Particularly, drug metabolites including hydrochlorothiazide and metformin reflect

313 antihypertensive and antidiabetic medications defined in LE8. Nevertheless, the associations

314 of MetaSig with LE8 score and incident CHD were consistent among participants with or

315 without history of hypertension or diabetes (**Fig. 3** and **Table S4**), and the MetaSig-CHD

316 association did not change after excluding those drug metabolites from the MetaSig [OR

317 (95% CI)=0.55 (0.48-0.64); P<0.001]. Moreover, excluding 29 unknown metabolites (X-)

318 from the MetaSig also did not change the MetaSig-CHD association [OR (95% CI)=0.58

319 (0.50-0.66); P<0.001]. Notably, the MetaSig also contains microbial metabolites, e.g.,

320 maltotetraose, anthranilate, indolebutyrate, and bile acids (taurohyocholate,

321 glycodeoxycholate 3-sulfate, 3b-hydroxy-5-cholenoic acid, and glycohyocholate), suggesting

322 the role of gut microbiome in host's CVH, which cannot be captured by questionnaires or

323 measurements of glucose, cholesterol, or blood pressure. Moreover, several metabolic

324 pathways related to CVH and CVD development were highlighted. For example, anthranilate,

325 indolebutyrate, picolinate, and serotonin are members of tryptophan metabolism pathway[50-52];

326 taurohyocholate, glycodeoxycholate 3-sulfate, 3b-hydroxy-5-cholenoic acid, and

327 glycohyocholate belong to secondary bile acid metabolism pathway[53,54]; alpha-tocopherol,

delta-tocopherol, and gamma-tocopherol/beta-tocopherol are vitamin E derivatives through

tocopherol metabolism pathway[55,56].

Importantly, the MetaSig was related to future CHD risk regardless of participants' age,

sex, race, SES, metabolic disease history, and even after adjustment for LE8. Further analyses

indicated that circulating metabolites could play a substantial mediating role linking LE8 and

reduced CHD risk. Moreover, our findings were replicated in a racially and geographically

different population, suggesting external validity and potential generalizability of our

findings. Taken together, our findings demonstrated that circulating metabolites could

complement LE8 to improve the precision of CVH assessment and predict CHD risk among

sociodemographically and geographically diverse populations.

To our knowledge, this is the first study that assessed the LE8 score, constructed its

metabolite signature, and associated LE8 score and its MetaSig with incident CHD in Black

and White Americans with low SES. Besides its novelty and inclusion of populations facing

socioeconomic challenges and health disparities, other strengths of our study include its

prospective design, comprehensive profiling of >1500 blood metabolites for a broad coverage

and improved ability to construct metabolite signature for LE8, and robustness of results

across populations with different sociodemographic and health status. Meanwhile, several

limitations of our current study need to be acknowledged. First, as MetaSig of LE8 was

identified using cross-sectional data from baseline blood samples, we cannot be certain as to

the directionality of LE8-MetaSig association, and mediation analysis assumed that LE8

score preceded MetaSig. Although several population- or animal-based studies have shown

the causal effects of LE8 components on blood metabolites[21,26,57-60], given that blood

metabolites might precede some LE8 components, the longitudinal association between LE8

adherence and circulating metabolites should be investigated. Second, given the observational

nature of our study, the causality is unable to be confirmed. However, the prospective design

reduces the concern of reverse causation for the LE8/MetaSig-CHD association. Third, we

cannot rule out the influence of residual confounding on the LE8/MetaSig-CHD association,

although we have adjusted for and stratified by major CHD risk factors. Fourth, the

concentrations of fasting glucose and HbA1c and SBP and DBP were not measured in SSCS;

thus, glucose score and blood pressure score were defined based on history of diabetes or

hypertension and use of medications, which may influence the accuracy of LE8 score.

Finally, the nested case-control design may overestimate the predictive ability of the LE8

score and its MetaSig. Therefore, our results should be further validated in other prospective

cohort studies.

In summary, our study assessed the LE8 score and identified MetaSig of LE8 among

low-income Black and White Americans. We found that both LE8 score and its MetaSig were

inversely associated with risk of CHD, consistently among participants with varied

sociodemographic and metabolic health status. Our identified metabolite signature may

provide an objective and comprehensive measure of LE8 and its metabolic underpinning,

which may help improve the precision of CVH assessment and facilitate more effective and

personalized CHD prevention strategies in diverse populations. Further examination of our

identified metabolites may improve understanding of biological mechanisms as how

following LE8 benefits CHD prevention.

Acknowledgments

375 The authors thank the study participants of the SCCS and the SWMHS.

Funding

The Southern Community Cohort Study is funded by U01 CA202979, the Shanghai Women's

Health Study is funded by UM1 CA182910, and the Shanghai Men's Health Study is funded

by UM1 CA173640 from the National Cancer Institute (NCI) at the National Institutes of

Health (NIH). Biospecimens of these three cohort studies are managed by the Survey and

Biospecimen Shared Resource, which is supported in part by the Vanderbilt-Ingram Cancer

Center (P30 CA68485). This study is supported by R01 HL149779 from the National Heart,

Lung, and Blood Institute (NHLBI) at the NIH. The content is solely the responsibility of the

authors and does not necessarily represent the official views of the National Institutes of

Health.

Conflict of interest

389 The authors declared no conflict of interest.

References

1. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet* 2020;**396**:1204-1222. doi: 10.1016/s0140-6736(20)30925-9

2. Tsao CW, Aday AW, Almarzooq ZI*, et al.* Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. *Circulation* 2023. doi: 10.1161/cir.0000000000001123

3. Lloyd-Jones DM, Allen NB, Anderson CA*, et al.* Life's essential 8: updating and enhancing the American Heart Association's Construct of Cardiovascular Health: a presidential advisory from the American Heart Association. *Circulation* 2022;**146**:e18-e43. doi:

4. Wang X, Ma H, Li X*, et al.* Association of Cardiovascular Health With Life Expectancy Free of Cardiovascular Disease, Diabetes, Cancer, and Dementia in UK Adults. *JAMA Intern Med* 2023. doi: 10.1001/jamainternmed.2023.0015

5. Isiozor NM, Kunutsor SK, Voutilainen A, Laukkanen JA. Life's Essential 8 and the risk of cardiovascular disease death and all-cause mortality in Finnish men. *Eur J Prev Cardiol* 2023. doi: 10.1093/eurjpc/zwad040

6. Jin C, Li J, Liu F*, et al.* Life's Essential 8 and 10-Year and Lifetime Risk of Atherosclerotic Cardiovascular Disease in China. *Am J Prev Med* 2023. doi: 10.1016/j.amepre.2023.01.009

7. Yi J, Wang L, Guo X, Ren X. Association of Life's Essential 8 with all-cause and cardiovascular mortality among US adults: A prospective cohort study from the NHANES 2005-2014. *Nutr Metab Cardiovasc Dis* 2023. doi: 10.1016/j.numecd.2023.01.021

8. Xanthakis V, Enserro DM, Murabito JM*, et al.* Ideal cardiovascular health: associations

with biomarkers and subclinical disease and impact on incidence of cardiovascular disease in

the Framingham Offspring Study. *Circulation* 2014;**130**:1676-1683. doi:

9. Gaye B, Tafflet M, Arveiler D*, et al.* Ideal cardiovascular health and incident

cardiovascular disease: heterogeneity across event subtypes and mediating effect of blood

biomarkers: the prime study. *Journal of the American Heart Association* 2017;**6**:e006389. doi:

10. Després JP. Predicting longevity using metabolomics: a novel tool for precision lifestyle

medicine? *Nat Rev Cardiol* 2020;**17**:67-68. doi: 10.1038/s41569-019-0310-2

11. Clish CB. Metabolomics: an emerging but powerful tool for precision medicine. *Molecular*

Case Studies 2015;**1**:a000588. doi:

12. Li J, Guasch-Ferré M, Chung W*, et al.* The Mediterranean diet, plasma metabolome, and

cardiovascular disease risk. *Eur Heart J* 2020;**41**:2645-2656. doi: 10.1093/eurheartj/ehaa209

13. Chen L, Zhernakova DV, Kurilshikov A*, et al.* Influence of the microbiome, diet and

genetics on inter-individual variation in the human plasma metabolome. *Nat Med* 2022. doi:

10.1038/s41591-022-02014-8

14. Wang F, Baden MY, Guasch-Ferré M*, et al.* Plasma metabolite profiles related to plant-

based diets and the risk of type 2 diabetes. *Diabetologia* 2022;**65**:1119-1132. doi:

10.1007/s00125-022-05692-8

15. Chen GC, Chai JC, Xing J*, et al.* Healthful eating patterns, serum metabolite profile and

risk of diabetes in a population-based prospective study of US Hispanics/Latinos. *Diabetologia*

2022;**65**:1133-1144. doi: 10.1007/s00125-022-05690-w

16. Shah RV, Steffen LM, Nayor M*, et al.* Dietary metabolic signatures and cardiometabolic

risk. *European Heart Journal* 2022. doi:

17. Kemppainen SM, Fernandes Silva L, Lankinen MA, Schwab U, Laakso M. Metabolite

Signature of Physical Activity and the Risk of Type 2 Diabetes in 7271 Men. *Metabolites*

2022;**12**. doi: 10.3390/metabo12010069

18. Kujala UM, Mäkinen VP, Heinonen I*, et al.* Long-term leisure-time physical activity and

serum metabolome. *Circulation* 2013;**127**:340-348. doi: 10.1161/circulationaha.112.105551

19. Ding M, Zeleznik OA, Guasch-Ferre M*, et al.* Metabolome-Wide Association Study of the

Relationship Between Habitual Physical Activity and Plasma Metabolite Levels. *Am J*

Epidemiol 2019;**188**:1932-1943. doi: 10.1093/aje/kwz171

20. Tan Y, Barr DB, Ryan PB*, et al.* High-resolution metabolomics of exposure to tobacco

smoke during pregnancy and adverse birth outcomes in the Atlanta African American maternal-

child cohort. *Environ Pollut* 2022;**292**:118361. doi: 10.1016/j.envpol.2021.118361

21. Xu T, Holzapfel C, Dong X*, et al.* Effects of smoking and smoking cessation on human

serum metabolite profile: results from the KORA cohort study. *BMC Med* 2013;**11**:60. doi:

10.1186/1741-7015-11-60

22. Gu F, Derkach A, Freedman ND*, et al.* Cigarette smoking behaviour and blood

metabolomics. *Int J Epidemiol* 2016;**45**:1421-1432. doi: 10.1093/ije/dyv330

23. Bos MM, Goulding NJ, Lee MA*, et al.* Investigating the relationships between

unfavourable habitual sleep and metabolomic traits: evidence from multi-cohort multivariable

regression and Mendelian randomization analyses. *BMC Med* 2021;**19**:69. doi:

10.1186/s12916-021-01939-0

24. Fritz J, Huang T, Depner CM*, et al.* Sleep duration, plasma metabolites, and obesity and

diabetes: A metabolome-wide association study in US women. *Sleep* 2022. doi:

10.1093/sleep/zsac226

25. Topriceanu CC, Tillin T, Chaturvedi N, Joshi R, Garfield V. The association between

plasma metabolites and sleep quality in the Southall and Brent Revisited (SABRE) Study: A

cross-sectional analysis. *J Sleep Res* 2021;**30**:e13245. doi: 10.1111/jsr.13245

26. Huang T, Zeleznik OA, Poole EM*, et al.* Habitual sleep quality, plasma metabolites and

risk of coronary heart disease in post-menopausal women. *Int J Epidemiol* 2019;**48**:1262-1274.

doi: 10.1093/ije/dyy234

27. Pan XF, Chen ZZ, Wang TJ*, et al.* Plasma metabolomic signatures of obesity and risk of

type 2 diabetes. *Obesity (Silver Spring)* 2022. doi: 10.1002/oby.23549

28. Ottosson F, Smith E, Ericson U*, et al.* Metabolome-Defined Obesity and the Risk of Future

Type 2 Diabetes and Mortality. *Diabetes Care* 2022;**45**:1260-1267. doi: 10.2337/dc21-2402

29. Signorello LB, Hargreaves MK, Blot WJ. The Southern Community Cohort Study:

investigating health disparities. *J Health Care Poor Underserved* 2010;**21**:26-37. doi:

10.1353/hpu.0.0245

30. Zheng W, Chow WH, Yang G*, et al.* The Shanghai Women's Health Study: rationale, study

design, and baseline characteristics. *Am J Epidemiol* 2005;**162**:1123-1131. doi:

10.1093/aje/kwi322

31. Shu XO, Li H, Yang G*, et al.* Cohort Profile: The Shanghai Men's Health Study. *Int J*

Epidemiol 2015;**44**:810-818. doi: 10.1093/ije/dyv013

32. Lloyd-Jones DM, Ning H, Labarthe D*, et al.* Status of Cardiovascular Health in US Adults

and Children Using the American Heart Association's New "Life's Essential 8" Metrics:

Prevalence Estimates From the National Health and Nutrition Examination Survey (NHANES),

2013 Through 2018. *Circulation* 2022;**146**:822-835. doi: 10.1161/circulationaha.122.060911

33. Mellen PB, Gao SK, Vitolins MZ, Goff DC. Deteriorating dietary habits among adults with

hypertension: DASH dietary accordance, NHANES 1988-1994 and 1999-2004. *Archives of*

internal medicine 2008;**168**:308-314. doi:

34. Chang RS, Xu M, Brown SH*, et al.* Relation of the Dietary Approaches to Stop

Hypertension Dietary Pattern to Heart Failure Risk and Socioeconomic Status (from the

Southern   Community   Cohort   Study).   *Am   J   Cardiol*   2022;**169**:71-77.   doi:

10.1016/j.amjcard.2021.12.043

35. Yu D, Zhang X, Xiang YB*, et al.* Adherence to dietary guidelines and mortality: a report

from prospective cohort studies of 134,000 Chinese adults in urban Shanghai. *Am J Clin Nutr*

2014;**100**:693-700. doi: 10.3945/ajcn.113.079194

36. Evans AM, DeHaven CD, Barrett T, Mitchell M, Milgram E. Integrated, nontargeted

ultrahigh   performance   liquid   chromatography/electrospray   ionization   tandem   mass

spectrometry platform for the identification and relative quantification of the small-molecule

complement of biological systems. *Anal Chem* 2009;**81**:6656-6667. doi: 10.1021/ac901536h

37. Zou H, Hastie T. Regularization and variable selection via the elastic net. *Journal of the*

royal statistical society: series B (statistical methodology) 2005;**67**:301-320. doi:

38. Kuhn M. Building predictive models in R using the caret package. *Journal of statistical*

software 2008;**28**:1-26. doi:

39. Friedman J, Hastie T, Tibshirani R. Regularization paths for generalized linear models via

coordinate descent. *Journal of statistical software* 2010;**33**:1. doi:

40. Tingley D, Yamamoto T, Hirose K, Keele L, Imai K. Mediation: R package for causal

mediation analysis. 2014. doi:

41. Huffman MD, Capewell S, Ning H*, et al.* Cardiovascular health behavior and health factor changes (1988-2008) and projections to 2020: results from the National Health and Nutrition Examination Surveys. *Circulation* 2012;**125**:2595-2602. doi: 10.1161/circulationaha.111.070722

42. Pilkerton CS, Singh SS, Bias TK, Frisbee SJ. Changes in Cardiovascular Health in the United States, 2003-2011. *J Am Heart Assoc* 2015;**4**:e001650. doi: 10.1161/jaha.114.001650

43. Haynes N, Kaur A, Swain J, Joseph JJ, Brewer LC. Community-Based Participatory Research to Improve Cardiovascular Health Among US Racial and Ethnic Minority Groups. *Curr Epidemiol Rep* 2022;**9**:212-221. doi: 10.1007/s40471-022-00298-5

44. Wishart DS. Emerging applications of metabolomics in drug discovery and precision medicine. *Nature reviews Drug discovery* 2016;**15**:473-484. doi:

45. Cirulli ET, Guo L, Leon Swisher C*, et al.* Profound Perturbation of the Metabolome in Obesity Is Associated with Health Risk. *Cell Metab* 2019;**29**:488-500.e482. doi: 10.1016/j.cmet.2018.09.022

46. Delgado-Velandia M, Gonzalez-Marrachelli V, Domingo-Relloso A*, et al.* Healthy lifestyle, metabolomics and incident type 2 diabetes in a population-based cohort from Spain. *Int J Behav Nutr Phys Act* 2022;**19**:8. doi: 10.1186/s12966-021-01219-3

47. Rothwell JA, Murphy N, Bešević J*, et al.* Metabolic Signatures of Healthy Lifestyle Patterns and Colorectal Cancer Risk in a European Cohort. *Clin Gastroenterol Hepatol* 2022;**20**:e1061-e1082. doi: 10.1016/j.cgh.2020.11.045

48. Assi N, Gunter MJ, Thomas DC*, et al.* Metabolic signature of healthy lifestyle and its

relation with risk of hepatocellular carcinoma in a large European cohort. *Am J Clin Nutr* 2018;**108**:117-126. doi: 10.1093/ajcn/nqy074

49. Si J, Li J, Yu C*, et al.* Improved lipidomic profile mediates the effects of adherence to healthy lifestyles on coronary heart disease. *Elife* 2021;**10**. doi: 10.7554/eLife.60999

50. Wirleitner B, Rudzite V, Neurauter G*, et al.* Immune activation and degradation of tryptophan in coronary heart disease. *European journal of clinical investigation* 2003;**33**:550-554. doi:

51. Mangge H, Stelzer I, Reininghaus E*, et al.* Disturbed tryptophan metabolism in cardiovascular disease. *Current medicinal chemistry* 2014;**21**:1931-1937. doi:

52. Liu G, Chen S, Zhong J, Teng K, Yin Y. Crosstalk between tryptophan metabolism and cardiovascular disease, mechanisms, and therapeutic implications. *Oxidative Medicine and Cellular Longevity* 2017;**2017**. doi:

53. Fan Y, Pedersen O. Gut microbiota in human metabolic health and disease. *Nat Rev Microbiol* 2021;**19**:55-71. doi: 10.1038/s41579-020-0433-9

54. Agus A, Clément K, Sokol H. Gut microbiota-derived metabolites as central regulators in metabolic disorders. *Gut* 2021;**70**:1174-1182. doi: 10.1136/gutjnl-2020-323071

55. Dietrich M, Traber MG, Jacques PF*, et al.* Does γ-tocopherol play a role in the primary prevention of heart disease and cancer? A review. *Journal of the American College of Nutrition* 2006;**25**:292-299. doi:

56. Mathur P, Ding Z, Saldeen T, Mehta JL. Tocopherols in the prevention and treatment of atherosclerosis and related cardiovascular disease. *Clinical cardiology* 2015;**38**:570-576. doi:

57. Würtz P, Wang Q, Kangas AJ*, et al.* Metabolic signatures of adiposity in young adults:

Mendelian randomization analysis and effects of weight change. *PLoS Med* 2014;**11**:e1001765.

doi: 10.1371/journal.pmed.1001765

58. Lauterbach MA, Latz E, Christ A. Metabolomic Profiling Reveals Distinct and Mutual

Effects of Diet and Inflammation in Shaping Systemic Metabolism in Ldlr(-/-) Mice.

Metabolites 2020;**10**. doi: 10.3390/metabo10090336

59. Sato S, Dyar KA, Treebak JT*, et al.* Atlas of exercise metabolism reveals time-dependent

signatures of metabolic homeostasis. *Cell Metabolism* 2022;**34**:329-345. e328. doi:

60. Cruickshank-Quinn CI, Mahaffey S, Justice MJ*, et al.* Transient and persistent

metabolomic changes in plasma following chronic cigarette smoke exposure in a mouse model.

PloS one 2014;**9**:e101855. doi:

Figure legends

Fig. 1. Overview of the current study. This study involved two nested case-control metabolomics studies within Southern Community Cohort Study (SCCS, primary cohort) and Shanghai Women's and Men's Health Studies (SWMHS, validation cohort). In the follow-up visits, participants with incident coronary heart disease (CHD) were identified and matched with controls by enrollment age, sex, race, fasting time, and time between sample collection and lab processing. After excluding 8 samples that did not pass metabolomics quality control, 1194 SCCS participants and 598 SWMHS participants were included. Metabolite signature of Life's Essential 8 (LE8) were identified using elastic net regression with leave-one-out cross-validation in SCCS. The associations of LE8 score and its metabolite signature with risk of CHD were evaluated by conditional logistic regression adjusted for confounders. Mediation analysis was performed to assess the potential mediating role of metabolite signature on the LE8-CHD association. External validity of the identified metabolite signature related to LE8 score and CHD risk was investigated in SWMHS.

Abbreviations: SCCS, Southern Community Cohort Study; SWMHS, Shanghai Women's and Men's Health Studies; CHD, coronary heart disease; LE8, Life's Essential 8; MetaSig, metabolite signature.

Fig. 2. The metabolite signature of LE8 and its association with risk of CHD. (A) Top 30 metabolites selected by elastic net regression in SCCS. Metabolites were ranked by the absolute value of regression coefficients. **(B)** *Spearman* correlation between MetaSig and LE8 score in SCCS. The dashed line denotes median LE8 score. **(C)** *Spearman* correlation

between MetaSig and LE8 score in SWMHS. **(D)** The mediation effect of MetaSig on the

association between LE8 score and risk of CHD in SCCS. **(E)** The mediation effect of

MetaSig on the association between LE8 score and risk of CHD in SWMHS.

Abbreviations: SCCS, Southern Community Cohort Study; SWMHS, Shanghai Women's

and Men's Health Studies; LE8, Life's Essential 8; MetaSig, metabolite signature; ACME,

average causal mediation effects; ADE, average direct effects; CHD, coronary heart disease.

Fig. 3. Subgroup analyses for the associations of LE8 score and its metabolite signature

with risk of CHD in SCCS. (A) Subgroup analysis for the association between LE8 score

and risk of CHD. **(B)** Subgroup analysis for the association between MetaSig and risk of

CHD. Conditional logistic regression models were used, adjusted for potential confounders.

For income, lower income denotes low income and higher income denotes middle and high

income.

Abbreviations: SCCS, Southern Community Cohort Study; MetaSig, metabolite signature;

CHD, coronary heart disease; LE8, Life's Essential 8; OR, odds ratio; CI, confidence interval.

592 **Table 1. Characteristics of study participants in the Southern Community Cohort Study**

	Black participants (N=598)		White participants (N=596)	
	CHD (N=299)	Control (N=299)	CHD (N=298)	Control (N=298)
Age, years	54.9 (8.8)	54.7 (8.7)	55.2 (8.7)	55.1 (8.6)
Male, n (%)	149 (49.8)	149 (49.8)	148 (49.7)	148 (49.7)
Education, n (%)				
Less than high school	120 (40.1)	109 (36.5)	108 (36.2)	84 (28.2)
Completed high school	107 (35.8)	108 (36.1)	118 (39.6)	118 (39.6)
Vocational school or some college	57 (19.1)	60 (20.1)	52 (17.4)	54 (18.1)
College or graduate school	15 (5.0)	22 (7.4)	20 (6.7)	42 (14.1)
Income, n (%)*				
Low	194 (64.9)	185 (61.9)	196 (65.8)	167 (56.0)
Middle	100 (33.4)	104 (34.8)	92 (30.9)	111 (37.2)
High	5 (1.7)	10 (3.3)	10 (3.4)	20 (6.7)
Alcohol intake, n (%)**				
None	154 (51.5)	140 (46.8)	175 (58.7)	140 (47.0)
Moderate	94 (31.4)	107 (35.8)	98 (32.9)	129 (43.3)
Heavy	51 (17.1)	52 (17.4)	25 (8.4)	29 (9.7)
Family history of CHD, n (%)	107 (35.8)	89 (29.8)	168 (56.4)	142 (47.7)
History of diabetes, n (%)	116 (38.8)	56 (18.7)	96 (32.2)	40 (13.4)
History of dyslipidemia, n (%)	102 (34.1)	91 (30.4)	155 (52.0)	108 (36.2)
History of hypertension, n (%)	210 (70.2)	179 (59.9)	177 (59.4)	133 (44.6)
LE8 score	45.9 (11.9)	52.2 (13.2)	45.0 (13.5)	51.5 (13.5)
LE8 score category, n (%)***				
High (80-100)	0 (0)	7 (2.3)	3 (1.0)	10 (3.4)
Moderate (50-79)	114 (38.1)	174 (58.2)	100 (33.6)	148 (49.7)
Low (0-49)	185 (61.9)	118 (39.5)	195 (65.4)	140 (47.0)
Health behaviors score	43.8 (18.4)	47.4 (20.5)	42.0 (19.2)	46.3 (21.0)
Health factors score	47.2 (20.4)	56.7 (21.3)	48.0 (20.7)	56.2 (20.1)
Diet score	39.8 (32.2)	41.6 (30.6)	36.9 (30.3)	40.8 (32.3)
Physical activity score	22.8 (39.8)	24.2 (40.5)	19.9 (38.8)	21.3 (39.1)
Smoking score	43.0 (42.2)	47.8 (42.5)	40.0 (40.3)	46.5 (42.0)
Sleep score	72.3 (29.2)	77.1 (26.6)	71.2 (29.7)	78.1 (26.6)
BMI score	50.0 (34.5)	56.9 (35.3)	50.4 (34.1)	57.7 (34.2)
Blood lipids score	36.8 (32.8)	44.6 (31.8)	25.8 (28.7)	27.9 (27.6)
Blood glucose score	54.3 (34.3)	69.6 (30.0)	60.9 (34.0)	73.3 (26.7)
Blood pressure score	47.7 (35.1)	55.8 (37.3)	54.9 (38.3)	65.9 (38.9)

Data were mean (standard deviation) or n (%) as indicated.

*Annual household income <$15,000, $15,000 to <$25,000, and ≥$25,000 for low, middle, and high levels of

income, respectively.

**Alcohol intake was grouped as none, moderate (>0 to ≤2 drinks per day in men or >0 to ≤1 drink per day in

women; 1 drink = 14 g ethanol), and heavy drinking (>2 drinks per day in men or >1 drink per day in women).

***The cutoffs were provided by the American Heart Association (Lloyd-Jones *et al.*, 2022).

Abbreviations: CHD, coronary heart disease; LE8, Life's Essential 8; BMI, body mass index.

Table 2. The associations of LE8 score, health behaviors score, health factors score and their related metabolite signatures with risk of CHD*

		OR (95% CI)	*P*
SCCS			
LE8	LE8 score	0.61 (0.53-0.69)	< 0.001
	MetaSig	0.57 (0.49-0.65)	< 0.001
	MetaSig (adjusting for LE8 score)	0.66 (0.55-0.78)	< 0.001
Health behaviors	Health behaviors score	0.77 (0.67-0.88)	< 0.001
	MetaSig	0.73 (0.63-0.85)	< 0.001
	MetaSig (adjusting for health behaviors score)	0.79 (0.67-0.94)	0.007
Health factors	Health factors score	0.61 (0.53-0.7)	< 0.001
	MetaSig	0.57 (0.49-0.66)	< 0.001
	MetaSig (adjusting for health factors score)	0.68 (0.55-0.84)	< 0.001
SWMHS			
LE8	LE8 score	0.52 (0.42-0.65)	< 0.001
	MetaSig	0.57 (0.46-0.69)	< 0.001
	MetaSig (adjusting for LE8 score)	0.69 (0.55-0.86)	< 0.001
Health behaviors	Health behaviors score	0.73 (0.59-0.9)	0.003
	MetaSig	0.69 (0.55-0.87)	0.001
	MetaSig (adjusting for health behaviors score)	0.77 (0.59-0.99)	0.043
Health factors	Health factors score	0.5 (0.4-0.62)	< 0.001
	MetaSig	0.57 (0.47-0.7)	< 0.001
	MetaSig (adjusting for health factors score)	0.80 (0.62-1.04)	0.093

* For associations of LE8 score and its related metabolite signature with risk of CHD, we used the conditional logistic regression, adjusted for age, education, income, alcohol intake, family history of CHD. For associations of health behaviors score and health factors score and their related metabolite signatures with risk of CHD, we used the conditional logistic regression, adjusted for age, education, income, alcohol intake, family history of CHD, and mutual adjustments of health factors score/health behaviors score.

Abbreviations: SCCS, Southern Community Cohort Study; SWMHS, Shanghai Women's and Men's Health Studies; CHD, coronary heart disease; LE8, Life's Essential 8; MetaSig, metabolite signature; OR, odds ratio; CI, confidence interval.

611   **Fig. 1. Overview of the current study**

612
613

Fig. 2. The metabolite signature of LE8 and its association with risk of CHD

Fig. 3. Subgroup analyses for the associations of LE8 score and its metabolite signature with risk of CHD in SCCS